NIH chief vows to clear development bottlenecks

NIH chief Francis Collins told a gathering of pharmaceutical scientists his agency needs to take an engineering approach to eliminate anything that slows drug development. Early discovery and preclinical development are well-known bottlenecks, and Collins said identifying new targets for approved drugs or compounds abandoned in the clinical stage will help the industry get more drugs to market. Story

Suggested Articles

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.